This dynamic, adaptive approach is not standardised in most other cancers save CML where dose and/or type of TKI therapy is adjusted based on results of sequential MRD-testing for BCR::ABL1. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.